International Clinical Trials Day 2019
20 May 2019
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
We want to take today to say a special thank you to our wonderful Clinical Trials team, and extend our appreciation to the many thousands of dedicated people that undertake clinical trials to advance medicine and treatments for patients. Today is also an opportunity to recognise patients and their contribution to finding a cure by choosing to participate in our trials.
Our 20-person team based at the Poche Centre is currently coordinating 18 actively recruiting trials, while maintaining follow-up for a further 23. The trials coordinated by the team range from surgical and dermatological trials, through the spectrum of available medical and radiation oncology trials, including immunotherapy, targeted therapy, and radiation therapy. In 2018, 244 new patients were enrolled in clinical trials at MIA, while 665 were in the follow-up stages.
“We are very fortunate here at MIA to have an extremely hardworking and inspiring Clinical Trials team who are one hundred percent dedicated to our patients,” says Co-Medical Director Professor Richard Scolyer.
Co-Medical Director Professor Georgina Long adds, “Clinical trials lead to advances in treatment that create better outcomes for our patients – continually pushing the boundaries and conducting these trials is what is going to help us achieve our goal of zero deaths of melanoma.”
International Clinical Trials Day commemorates the day Scottish doctor James Lind began the first ever clinical trial in 1747, using different groups of sailors to identify the link between fruit and the prevention of scurvy. Lind changed modern medicine with his study, so every year International Clinical Trials Day is celebrated to appreciate and highlight the work of those in Clinical Trials.
Clinical Trials Manager Maria Gonzalez echoed the sentiments of the whole team, “We all come to work each day for the same reason: to help patients and find a cure.”
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.